2. Search Result
Search Result
Results for "

CXJ-2080

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-183070
    CXJ2080

    		PROTACs CDK Apoptosis Cancer
    CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia .
    CXJ2080
  • HY-183071
    CDK7 ligand 3

    		Ligands for Target Protein for PROTAC CDK Cancer
    CDK7 ligand 3 is a target protein ligand for CXJ2080 (HY-183070), which be used for the research of acute leukemia .
    CDK7 ligand 3
  • HY-183072
    (S)-(S,R,S,R)-AHPC-Me-N3-C6-COOH

    		E3 Ligase Ligand-Linker Conjugates Cancer
    (S)-(S,R,S,R)-AHPC-Me-N3-C6-COOH (Compound 12) is an E3 ligase ligand-linker conjugate containing an E3 ligase ligand (HY-170348) and a PROTAC linker (HY-W586116). (S)-(S,R,S,R)-AHPC-Me-N3-C6-COOH can be used for synthesis of PROTAC, such as CXJ2080 (HY-183070) .
    (S)-(S,R,S,R)-AHPC-Me-N3-C6-COOH

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: